

1 **Title page**

2 ODIASP: An Open User-Friendly Software for Automated SMI Determination—Application
3 to an Inpatient Population

4

5 Katia Charrière¹, Antoine Ragusa², Béatrice Genoux¹, Antoine Vilotitch³, Svetlana Artemova¹,
6 Charlène Dumont¹, Paul-Antoine Beaudoin^{1,6}, Pierre-Ephren Madiot¹, Gilbert R. Ferretti⁴, Ivan
7 Bricault⁴, Eric Fontaine⁵, Jean-Luc Bosson^{1,6}, Alexandre Moreau-Gaudry^{1,6}, Joris Giai^{1,6}, Cécile
8 Bétry⁷

9

10 ¹ Univ. Grenoble Alpes, Clinical Investigation Center-Technological Innovation, INSERM
11 CIC1406, CHU Grenoble Alpes, Public Health department, 38000 Grenoble, France

12 ² Univ. Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, TIMC, 38000
13 Grenoble, France

14 ³ Univ. Grenoble Alpes, Data Engineering Unit, Public Health Department, Grenoble Alpes
15 University Hospital, 38000 Grenoble, France.

16 ⁴ Univ. Grenoble Alpes, INSERM U1209, IAB, CHU Grenoble Alpes, Service de radiologie
17 diagnostique et interventionnelle, 38000 Grenoble, France

18 ⁵ Univ. Grenoble Alpes, INSERM U1055, LBFA, CHU Grenoble Alpes, Department of
19 Endocrinology, Diabetology and Nutrition, 38000 Grenoble, France

20 ⁶ Univ. Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble
21 Alpes, Public Health department, TIMC, 38000 Grenoble, France

22 ⁷ Univ. Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble
23 Alpes, TIMC, Department of Endocrinology, Diabetology and Nutrition, 38000 Grenoble,
24 France

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 Corresponding author

27 Prof. Cécile Bétry, MD-PhD

28 Université Grenoble Alpes

29 CHU Grenoble Alpes (CHUGA)

30 Service d'Endocrinologie Diabétologie Nutrition

31 Boulevard de la Chantourne

32 38700 La Tronche, France

33 cbetry@chu-grenoble.fr

34 Tel: +33 4 76 76 93 49

35 **Abstract**

36 **Background:** The diagnosis of malnutrition has evolved with the GLIM recommendations,
37 which advocate for integrating phenotypic criteria, including muscle mass measurement. The
38 GLIM framework specifically suggests using skeletal muscle index (SMI) assessed via CT scan
39 at the third lumbar level (L3) as a first-line approach. However, manual segmentation of muscle
40 from CT images is often time-consuming and infrequently performed in clinical practice. This
41 study aims to develop and validate an open-access, user-friendly software tool called ODIASP
42 for automated SMI determination.

43 **Methods:** Data were retrospectively collected from a clinical data warehouse at Grenoble Alpes
44 University Hospital, including epidemiological and imaging data from CT scans. All
45 consecutive adult patients admitted in 2018 to our tertiary center who underwent at least one
46 CT scan capturing images at the L3 vertebral level and had a recorded height were included.
47 The ODIASP tool combines two algorithms to automatically perform L3 slice selection and
48 skeletal muscle segmentation, ensuring a seamless process. Agreement between cross-sectional
49 muscle area (CSMA) values obtained via ODIASP and reference methodology was evaluated
50 using the intraclass correlation coefficient (ICC). The prevalence of reduced SMI was also
51 assessed.

52 **Results:** SMI values were available for 2,503 participants, 53.3% male, with a median age of
53 66 years [51-78] and a median BMI of 24.8 kg/m² [21.7-28.7]. There was substantial agreement
54 between the reference method and ODIASP (ICC: 0.971; 95% CI: 0.825 to 0.989) in a
55 validation subset of 674 CT scans. After correcting for systematic errors (a 5.8 cm² [5.4-6.3]
56 overestimation of the CSMA), the agreement improved to 0.984 (95% CI: 0.982 to 0.986),
57 indicating excellent agreement. The prevalence of reduced SMI was estimated at 9.1% overall

58 (11.0% in men and 6.6% in women). To facilitate usage, the ODIASP software is encapsulated
59 in a user-friendly interface.

60 Conclusions: This study demonstrates that ODIASP is a reliable tool for automated muscle
61 segmentation at the L3 vertebra level from CT scans. The integration of validated AI algorithms
62 into a user-friendly platform enhances the ability to assess SMI in diverse patient cohorts,
63 ultimately contributing to improved patient outcomes through more accurate assessments of
64 malnutrition and sarcopenia.

65 **Key words**

66 Sarcopenia, Malnutrition, Image Processing, Computer-Assisted, Computational Neural
67 Networks, Skeletal Muscle, Body composition

68 **Introduction**

69 Since the release of the GLIM recommendations, malnutrition diagnosis has been based
70 on both phenotypic and etiological criteria ¹. In current clinical practice, phenotypic criteria for
71 malnutrition primarily involve mainly Body Mass Index (BMI) and weight loss assessments ^{2,3}.
72 However, a large proportion of patients are not weighed during hospitalization ⁴. The GLIM
73 framework recommends that muscle mass assessments should be performed as a first-line
74 approach to detect muscle mass reduction using one of three methods: dual-energy x-ray
75 absorptiometry (DEXA), computerized tomography (CT) scan, or bioelectrical impedance
76 analysis (BIA). For CT, the cross-sectional muscle area (CSMA) at the third lumbar vertebra
77 (L3) is recommended to calculate the skeletal muscle index (SMI). However, manual
78 segmentation of muscle from CT images is time-consuming³.

79 AI algorithms have the potential to automate SMI determination, potentially extending
80 the use of CT scan for malnutrition diagnosis in clinical practice and across large volumes of
81 CT scans ⁵. Although research in AI-driven CT scan analysis is expanding, a significant gap
82 persists between technological advancements and clinical integration. We hypothesize that part
83 of this gap arises from the lack of user-friendly interfaces that facilitate the application of these
84 algorithms. Furthermore, few comprehensive solutions exist that provide a fully automated
85 pipeline for SMI determination, including both L3 slice identification and muscle segmentation.
86 Existing tools are often developed within specific cohorts, limiting their applicability for
87 malnutrition screening in broader, unselected patient populations ⁶⁻⁸.

88 This study is a part of a larger research project: the Optimization of the DIagnosis of
89 SarcoPenia through the automated determination of SMI (ODIASP) study. Our primary
90 objective was to develop and validate an open-access, user-friendly software for the automated
91 determination of the Skeletal Muscle Index (SMI) in clinical research. Additionally, we aimed

- 92 to evaluate the potential of this tool in identifying the risk of reduced SMI within a cohort of
- 93 patients managed at a tertiary hospital.

94 Methods

95

96 Ethics statement

97 The ODIASP study was conducted in accordance with the ethical standards laid down
98 in the 1964 Declaration of Helsinki and its later amendments. Ethical approval was obtained on
99 18 August 2021 by the regional ethics committee (CECIC Rhône-Alpes-Auvergne, Clermont-
100 Ferrand, IRB 5891). In compliance with current French legislation for retrospective studies
101 using clinical data, participants were individually informed that their data could be used for
102 research purposes (in line with the MR-004 CNIL reference methodology). Individuals who
103 objected to the use of their data or those with incomplete or outdated contact information were
104 excluded from the study.

105

106 Study participants

107 All consecutive participants aged 18 years and older, admitted to Grenoble University
108 Hospital (CHU Grenoble Alpes) between January and December 2018, who underwent at least
109 one CT scan potentially capturing images at the L3 vertebral level and who had a recorded
110 height were retrospectively included in the study. Participants with non-abdominal CT scans,
111 including spinal or thoracic CT scans, were also eligible, as these may contain images at the L3
112 level. This inclusion was particularly relevant for assessing whether the ODIASP software
113 could effectively detect CT scans that lacked an L3 slice. When multiple CT scans were
114 available for a patient during the inclusion period, the scan most likely to include the L3 slice
115 was selected for analysis. A subset of this population had been previously defined for
116 preliminary research⁹ and was utilized for validation.

117 Data collection

118 Data were retrospectively collected from the clinical data warehouse (CDW) PREDIMED
119 (French acronym for *Plateforme de Recueil et d'Exploitation des Données bloMEDicales*),
120 implemented at the Grenoble Alpes University Hospital ^{10,11}. All structured data were
121 pseudonymized and CT scans were de-identified. This de-identification of CT scans was carried
122 out by: 1) removing all identifiable Digital Imaging and Communication in Medicine (DICOM)
123 tags following the basic profile recommendations of the DICOM standard¹, and 2) excluding
124 all derived images (i.e., images where pixel values are derived or computed from other images,
125 such as screenshots or dose reports) based on the 'ImageType' DICOM attribute.

126 The following data were collected

- 127 - General data: age, sex, height, weight
- 128 - Imaging data: CT scans, including abdominal area, in DICOM format with
129 metadata. Since contrast enhancement does not influence cross-sectional skeletal
130 muscle area, both CT images with and without contrast administration were eligible
131 ^{12,13}. CT images could originate from different CT machines (Optima CT660 GE
132 Healthcare, Revolution CT GE Healthcare, Siemens Somatom Definition Edge,
133 Revolution HD GE Healthcare, Revolution EVO GE Healthcare , Toshiba Aquilion
134 and Siemens Somatom Definition AS+).

135

136 Cross sectional muscle area (CSMA) determination

137 *Reference Method*


138 All processing was performed on a single GPU machine (NVIDIA TITAN RTX 16
139 graphics card, a 3.7 GHz CPU, and 64 GB of RAM) with an Intel(R) Xeon(R) W-2135
140 processor. The third lumbar (L3) vertebra was manually identified by a medical expert on the
141 sagittal reconstruction using the Picture Archiving and Communication System (PACS) in

¹ https://dicom.nema.org/medical/dicom/current/output/html/part15.html#sect_E.1.1

142 DICOM format. For each participant, a slice approximately halfway along the vertebra was
143 selected for muscle segmentation, with the identification of slices at both the lower and upper
144 extremities. Skeletal muscle was then manually segmented with SliceOmatic Version 5.0
145 (Tomovision, Canada) according to previously published methods to obtain the CSMA⁹. The
146 abdominal muscles (transversus abdominis, external and internal obliques and rectus
147 abdominis), the paraspinal muscles (erector spinae and quadratus lumborum) and the psoas
148 muscle were segmented using Hounsfield unit (HU) values ranging from -29 to 150¹⁴.

149 *ODIASP tool*

150 The ODIASP tool integrates two open-source algorithms: 1) for the automatic selection
151 of a slice at the level of the L3 vertebra, and 2) for the automatic segmentation of skeletal muscle
152 in this slice (Figure 1). For the first step, we employed the L3 slice selection algorithm
153 developed by Bridge et al.¹⁵ This algorithm, based on a DenseNet Convolutional Neural
154 Network (CNN), was trained and validated using ODIASP project data through 5-fold cross-
155 validation. A batch size of 64 images, a learning rate of 0.001, and a dropout rate of 0 were
156 selected, while other hyperparameters proposed by Bridge et al. were maintained during the
157 training phase. For the second step, we utilized the AutoMATiCA algorithm developed by Paris
158 et al.¹⁶. The proposed U-Net model for automated segmentation of skeletal muscle was
159 previously validated on ODIASP project CT data⁹.



160

161 Figure 1. Schematic overview of the architecture of the ODIASP tool

162 The ODIASP tool is based on two previously published algorithms from Bridge et al. ¹⁵ and
163 Paris et al. ¹⁶.


164 Statistical analysis

165 Characteristics of the cohort were presented as medians with interquartile ranges (IQR)
166 or using frequencies and proportions depending on their nature. The agreement between the
167 CSMA values calculated by ODIASP and those obtained using the reference methodology was
168 assessed using the intraclass correlation coefficient (ICC) along with 95% confidence intervals.
169 This analysis was complemented with a mixed regression model. The interpretation of the
170 strength of agreement between the two methods was based on the criteria established by Koo
171 and Li: an ICC value < 0.5 indicated poor reliability, a value between 0.5 and 0.75 indicated
172 moderate reliability, a value between 0.75 and 0.90 indicated substantial reliability, and a value
173 > 0.90 indicated excellent reliability ¹⁷. For determining the reduction in SMI within our sample,
174 thresholds were derived from the study by van der Werf et al ¹⁸ and are applicable only to the
175 subpopulation aged 20 to 79 years with a BMI ranging from 17 to 35 kg/m². and were applicable
176 only to the subsample of participants aged 20 to 79 years with a BMI ranging from 17 to 35
177 kg/m². Statistical analyses were conducted using Stata (version 15) with p-values <0.05
178 considered statistically significant and without adjustment for test multiplicity.

179 Results

180 Participant inclusion and characteristics

181 A total of 3300 participants were included and 2503 participants were analyzed (Figure
182 2). Their median age was 66 [51–78] years with 1334 (53.3%) males. The median BMI was
183 24.8 [21.7–28.7] kg/m², with 174 (7.3%) having a BMI < 18.5 kg/m² and 459 (19.3%) classified
184 as obese. The median SMI was 45.1 [38.4–52.5] cm²/m². Participants were hospitalized in the
185 following units: day hospital (11.0%), medicine (27.4%), geriatrics (2.8%), surgery (10.4%),
186 intensive care (6.1%), rehabilitation (1.8%), and emergency care (40.5%).



187


188 Validation of the ODIASP tool

189 The ODIASP tool operates through two main steps: first, identifying a L3 slice and
190 second, segmenting the skeletal muscle (Figure 1). For the first step, we validated the algorithm

191 from Bridge et al. The algorithm correctly identified the L3 slice in 88% of cases (95% CI:
192 85.49 to 90.50, n=596). For slices outside the L3 level (n=80), the median distance from the
193 chosen L3 slice was -5.6 mm [-17.5 to 12.5], indicating that the slices were, on average, 5.6
194 mm below the lower extremity of the L3 vertebra. The algorithm for the second step, muscle
195 segmentation, was previously validated externally ⁹.

196 To validate the entire pipeline, we compared the cross-sectional muscle area (CSMA)
197 obtained using the reference method with that generated by the ODIASP tool in the validation
198 subset. ODIASP failed to provide results for two participants (Figure 2). There was substantial
199 agreement between the reference method and ODIASP (ICC: 0.971; 95% CI: 0.825 to 0.989)
200 (Figure 3). After correcting for systematic errors (a 5.8 cm² [5.4-6.3] overestimation of the
201 CSMA), there was excellent agreement (ICC:0.984, 95% CI: 0.982 to 0.986).

202



203

204 Figure 3. Scatterplot comparing cross-sectional muscle area (CSMA) measurements obtained
205 with the reference method and the ODIASP tool (n = 674).

206 Each data point represents an individual measurement, and the dashed line signifies
207 perfect agreement between the two methods. The proximity of data points to the dashed line
208 indicates a high degree of agreement.

209

210 An Open-Access and User-Friendly Interface

211 To facilitate the use of the ODIASP tool, we encapsulated the code into a user-friendly
212 software interface (Figure 4A). The interface displays the sagittal view with the chosen L3 slice
213 localization, the L3 slice itself, and its segmentation, allowing for easy visual validation of
214 results (Figure 4B). This software is freely available at <https://odiasp.timc.fr/> (Figure 4C).



215

216 Figure 4. The ODIASP tool: an open access software with user-friendly interface

217 (A) User interface

218 (B) Example of muscle segmentation

219 (C) QR code for downloading the ODIASP Software

220 ODIASP allows processing of large sets of CT scans without the need for pre-treatment.

221 It takes approximately 4 minutes to analyze one CT scan. In some cases, ODIASP did not

222 correctly identify or segment muscle. However, the interface allows for quick visual inspection

223 of the results if necessary.

224 Risk of reduced SMI in a large cohort of hospitalized participants

225 Based on previously published cut-off values for individuals aged 20–79 years with a

226 BMI between 17 and 35 kg/m², 103 of 937 men (11.0%) and 46 of 699 women (6.6%) were

227 considered to have reduced skeletal muscle mass, representing a total of 9.1% of the participants

228 with an available cut-off¹⁸.

229 Discussion

230 This study aimed to develop and validate a tool for the automated determination of SMI
231 at the L3 vertebra level using CT scan in a large population. We integrated AI algorithms into
232 a user-friendly software, making advanced technologies accessible to clinical researchers who
233 may be unfamiliar with them.

234 Reliability of the ODIASP automated tool

235 Most previous studies have focused on tissue segmentation at the L3 level ^{16,19,20}, with
236 few addressing the challenge of developing a fully automated pipeline for L3 SMI
237 determination. To our knowledge, we are the first to develop and validate automated AI
238 software for L3 SMI determination in an unselected population of patients managed at a tertiary
239 hospital across various units, including emergency and intensive care. Previous tools have been
240 developed for specific populations, such as cancer patients ^{6,7} or mixed cohorts including
241 cancer, sepsis, and healthy subjects ⁸. Our approach involved utilizing previously published
242 algorithms and validating them in our cohort, demonstrating good reliability across a large
243 sample. We achieved accurate identification of most L3 slices, with 88% correctly positioned
244 at the L3 vertebra, which aligns with previous findings (Delrieu et al.: 91.2% and 74.1% in, two
245 datasets⁶). Slices identified outside of the L3 level showed a median deviation of -5.6 mm [-
246 17.5; 12.5], typically locating them at adjacent vertebrae, given the approximate height of
247 vertebrae (30 mm) and intervertebral disks (10 mm) ²¹. A prior study indicates that CSMA at
248 neighboring vertebrae are relatively comparable ²². The reliability of muscle segmentation was
249 previously validated ⁹, and our full pipeline demonstrated substantial to excellent reliability.

250 Clinical implications

251 The prevalence of reduced SMI has mainly been studied in cancer populations ²³⁻²⁵. To
252 our knowledge, our study is the first to assess it in a large cohort of unselected patients, with
253 the sole inclusion criteria being the availability of a CT scan. The cut-offs for defining reduced

254 SMI remains controversial, while the cut-offs proposed by Prado et al. ¹⁴ have been widely
255 used, they are specific to patients with obesity and cancer and can lead to an overestimation of
256 reduced SMI prevalence ²⁶. In our study, we referred to the cut-offs by Van der Werf et al.¹⁸,
257 which are applicable to a Caucasian population and align well with our predominantly
258 Caucasian cohort. Furthermore, Van der Werf et al. provide age- and BMI-specific cut-offs,
259 enhancing the relevance of our findings. Our research indicates that 9% of the patients in our
260 tertiary hospital setting have reduced muscle mass.

261 Study limitations

262 Several limitations should be acknowledged. First, we trained the algorithm of Bridge
263 et al. on our dataset since it was only available in an untrained version. Consequently, our tool
264 lacks full external validation. Second, when testing ODIASP on the analyzed populations, we
265 identified some processing failures. Human oversight remains essential for maintaining data
266 quality; thus, our software provides features for visual manual validation, in line with the recent
267 European Union AI Act emphasizes the necessity of human oversight in algorithmic decision-
268 making ²⁷. Third, processing large datasets can be time-consuming; for instance, analyzing
269 1,000 scans requires just over 24 hours with a standard desktop computer. However, the process
270 is fully automated and runs in the background. Our approach involved testing ODIASP under
271 real-life conditions, using scans with multiple series, including those that did not contain the L3
272 vertebra, which lengthened the process but reduced the time necessary to preprocess the data.
273 Additionally, it is important to acknowledge that some CT scans may have insufficient quality
274 for accurate segmentation, a factor that should be considered in future clinical research.. Lastly,
275 ODIASP tends to slightly overestimate the CSMA compared to the ground truth. This
276 discrepancy reflects a systematic error comparable to inter-expert variability and could be partly
277 influenced by the overestimation observed with AutoMATiCA or the fact that the ground truth
278 was constructed at our center by only two experts ^{9,16}.

279 Futures directions

280 Future work will focus on enhancing the reliability of our software. A strength of this
281 project is our access to diverse medical imaging data through the CDW PREDIMED, allowing
282 for the inclusion of patients from various units and with different pathologies. However, our
283 study is monocentric, which may lead to overfitting and limit generalizability. Traditional
284 training methods can overestimate model accuracy by about 20% due to hidden Data
285 Acquisition Bias-Induced Shortcuts (DABIS)²⁸. Strategies to increase reliability include using
286 external training datasets and applying appropriate data preparation and partitioning techniques
287 (training, validation, and testing sets) to improve generalizability²⁹⁻³¹. Additionally, methods
288 to address biases without external datasets can also be applied²⁸. Our objective is to develop
289 extensive cohorts for studying malnutrition and sarcopenia in inpatients. However, many
290 patients do not undergo abdominal CT scans. To address this limitation, we plan to enhance
291 ODIASP's capabilities to analyze chest CT scans, considering the growing interest in assessing
292 SMI at the T12 vertebra level³². We also plan to validate the segmentation of other tissues—
293 intermuscular, visceral, and subcutaneous adipose tissue—performed in AutoMATiCA before
294 integrating it into ODIASP¹⁶. It is important to note that ODIASP is not yet CE marked or FDA
295 approved, limiting its use to clinical research rather than routine practice. Our ultimate goal is
296 to deploy this software in clinical settings after obtaining all mandatory regulatory
297 authorization.

298

299 **Conclusion**

300 The results of this study demonstrate that ODIASP is a reliable tool for the automated
301 segmentation of muscles at the L3 vertebra level from CT scans. Integrating validated AI
302 algorithms into a user-friendly software platform can significantly enhance clinical researchers'
303 ability to assess SMI in large, diverse patient cohorts. We anticipate that our research will

- 304 facilitate a deeper understanding of the impact of reduced SMI, ultimately contributing to
- 305 improve patient outcomes through more accurate malnutrition and sarcopenia assessments.

306 **Funding**

307 This work was supported by a grant from the Regional Delegation for Clinical Research
308 of the University Hospital Grenoble Alpes in 2019 and MIAI@Grenoble Alpes, (ANR-19-
309 P3IA-0003). The funding bodies did not have any involvement in the design/conduct of the
310 research, in data analysis/interpretation, or in writing/approval of the manuscript.

311

312 **Conflict of interest Statement**

313 Katia Charrière, Antoine Ragusa, Béatrice Genoux, Antoine Vilotitch, Svetlana
314 Artemova, Charlène Dumont, Paul-Antoine Beaudoin, Pierre-Ephren Madiot, Gilbert R.
315 Ferretti, Ivan Bricault, Jean-Luc Bosson, Eric Fontaine, Alexandre Moreau-Gaudry, Joris Giai
316 and Cécile Bétry have no relevant conflict of interest to disclose.

317

318 **Ethical guidelines statement**

319 The ODIASP study was conducted in accordance with the ethical standards laid down
320 in the 1964 Declaration of Helsinki and its later amendments. Ethical approval was obtained on
321 18 August 2021 by the regional ethics committee (CECIC Rhône-Alpes-Auvergne, Clermont-
322 Ferrand, IRB 5891). In compliance with current French legislation for retrospective studies
323 using clinical data, participants were individually informed that their data could be used for
324 research purposes (in line with the MR-004 CNIL reference methodology)

325 References

- 326 1. Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi
327 T *et al.* GLIM criteria for the diagnosis of malnutrition - A consensus report from the global
328 clinical nutrition community. *Clin Nutr* 2019;**38**:1–9.
- 329 2. Ulmann G, Cherbuy C, Guerriero E, Jirka A, Le Gall M, Neuzillet C *et al.*
330 Modifications des recommandations de la Haute Autorité de santé concernant le diagnostic de
331 la dénutrition : application par les professionnels de la nutrition en pratique clinique. *Nutrition*
332 *Clinique et Métabolisme* 2023;**37**:168–175.
- 333 3. Barazzoni R, Jensen GL, Correia MITD, Gonzalez MC, Higashiguchi T, Shi HP *et al.*
334 Guidance for assessment of the muscle mass phenotypic criterion for the Global Leadership
335 Initiative on Malnutrition (GLIM) diagnosis of malnutrition. *Clinical Nutrition*
336 2022;**41**:1425–1433.
- 337 4. Lambert K, Ferguson A, Meletis M, Charlton K. How frequently are patients weighed
338 in hospital ? Results from a five-year cross-sectional audit of clinical practice in nine
339 hospitals. *Clinical Nutrition ESPEN* 2020;**36**:157–161.
- 340 5. Rozynek M, Kucybała I, Urbanik A, Wojciechowski W. Use of artificial intelligence
341 in the imaging of sarcopenia: A narrative review of current status and perspectives. *Nutrition*
342 2021;**89**:111227.
- 343 6. Delrieu L, Blanc D, Bouhamama A, Reyat F, Pilleul F, Racine V *et al.* Automatic
344 deep learning method for third lumbar selection and body composition evaluation on CT
345 scans of cancer patients. *Front Nucl Med* 2024;**3**.
- 346 7. Islam S, Kanavati F, Arain Z, Costa OFD, Crum W, Aboagye EO *et al.* Fully
347 automated deep-learning section-based muscle segmentation from CT images for sarcopenia
348 assessment. *Clinical Radiology* 2022;**77**:e363–e371.
- 349 8. Ha J, Park T, Kim H-K, Shin Y, Ko Y, Kim DW *et al.* Development of a fully
350 automatic deep learning system for L3 selection and body composition assessment on
351 computed tomography. *Sci Rep* 2021;**11**:21656.
- 352 9. Charrière K, Boulouard Q, Artemova S, Vilotitch A, Ferretti GR, Bosson J-L *et al.* A
353 comparative study of two automated solutions for cross-sectional skeletal muscle
354 measurement from abdominal computed tomography images. *Medical Physics* 2023;**50**:4973–
355 4980.
- 356 10. Artemova S, Madiot P-E, Caporossi A, Group P, Mossuz P, Moreau-Gaudry A.
357 PREDIMED: Clinical Data Warehouse of Grenoble Alpes University Hospital. *MEDINFO*
358 *2019: Health and Wellbeing e-Networks for All* 2019;1421–1422.
- 359 11. Charrière K, Madiot P-E, Artemova S, Tep P, Lenne C, Cohard B *et al.* ODIASP:
360 Clinically Contextualized Image Analysis Using the PREDIMED Clinical Data Warehouse,
361 Towards a Better Diagnosis of Sarcopenia. *Stud Health Technol Inform* 2022;**290**:1068–1069.
- 362 12. Paris MT, Furberg HF, Petruzella S, Akin O, Hötter AM, Mourtzakis M. Influence of
363 Contrast Administration on Computed Tomography-Based Analysis of Visceral Adipose and
364 Skeletal Muscle Tissue in Clear Cell Renal Cell Carcinoma. *JPEN J Parenter Enteral Nutr*
365 2018 doi:10.1002/jpen.1067.
- 366 13. van Vugt JLA, Coebergh van den Braak RRJ, Schippers HJW, Veen KM, Levolger S,
367 de Bruin RWF *et al.* Contrast-enhancement influences skeletal muscle density, but not
368 skeletal muscle mass, measurements on computed tomography. *Clin Nutr* 2017
369 doi:10.1016/j.clnu.2017.07.007.
- 370 14. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L *et al.*
371 Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of
372 the respiratory and gastrointestinal tracts: a population-based study. *The Lancet Oncology*
373 2008;**9**:629–635.

- 374 15. Bridge CP, Rosenthal M, Wright B, Kotecha G, Fintelmann F, Troschel F *et al.* Fully-
375 Automated Analysis of Body Composition from CT in Cancer Patients Using Convolutional
376 Neural Networks. 2018. pp. 204–213.
- 377 16. Paris MT, Tandon P, Heyland DK, Furberg H, Premji T, Low G *et al.* Automated
378 body composition analysis of clinically acquired computed tomography scans using neural
379 networks. *Clinical Nutrition* 2020;**39**:3049–3055.
- 380 17. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation
381 Coefficients for Reliability Research. *J Chiropr Med* 2016;**15**:155–163.
- 382 18. van der Werf A, Langius JAE, de van der Schueren MAE, Nurmohamed SA, van der
383 Pant KAMI, Blauwhoff-Buskermolen S *et al.* Percentiles for skeletal muscle index, area and
384 radiation attenuation based on computed tomography imaging in a healthy Caucasian
385 population. *Eur J Clin Nutr* 2018;**72**:288–296.
- 386 19. Shen H, He P, Ren Y, Huang Z, Li S, Wang G *et al.* A deep learning model based on
387 the attention mechanism for automatic segmentation of abdominal muscle and fat for body
388 composition assessment. *Quant Imaging Med Surg* 2023;**13**:1384–1398.
- 389 20. Pu L, Gezer NS, Ashraf SF, Ocak I, Dresser DE, Dhupar R. Automated segmentation
390 of five different body tissues on computed tomography using deep learning. *Med Phys*
391 2023;**50**:178–191.
- 392 21. Zhou SH, McCarthy ID, McGregor AH, Coombs RRH, Hughes SPF. Geometrical
393 dimensions of the lower lumbar vertebrae – analysis of data from digitised CT images. *Eur*
394 *Spine J* 2000;**9**:242–248.
- 395 22. Park J, Gil JR, Shin Y, Won SE, Huh J, You M-W *et al.* Reliable and robust method
396 for abdominal muscle mass quantification using CT/MRI: An explorative study in healthy
397 subjects. *PLoS One* 2019;**14**:e0222042.
- 398 23. Raoul P, Cintoni M, Coppola A, Alfieri S, Tortora G, Gasbarrini A *et al.* Preoperative
399 low skeletal muscle mass index assessed using L3-CT as a prognostic marker of clinical
400 outcomes in pancreatic cancer patients undergoing surgery: A systematic review and meta-
401 analysis. *Int J Surg* 2023 doi:10.1097/JS9.0000000000000989.
- 402 24. de Luis Roman D, López Gómez JJ, Muñoz M, Primo D, Izaola O, Sánchez I.
403 Evaluation of Muscle Mass and Malnutrition in Patients with Colorectal Cancer Using the
404 Global Leadership Initiative on Malnutrition Criteria and Comparing Bioelectrical Impedance
405 Analysis and Computed Tomography Measurements. *Nutrients* 2024;**16**:3035.
- 406 25. Anabtawi NM, Pasala MS, Grimshaw AA, Kharel P, Bal S, Godby K *et al.* Low
407 skeletal muscle mass and treatment outcomes among adults with haematologic malignancies:
408 A systematic review and meta-analysis. *J Cachexia Sarcopenia Muscle* 2024;**15**:1084–1093.
- 409 26. Caudron L, Bussy A, Artemova S, Charrière K, Lakkiss SE, Moreau-Gaudry A *et al.*
410 Sarcopenia diagnosis: comparison of automated with manual computed tomography
411 segmentation in clinical routine. *JCSM Rapid Communications* 2021;**4**:103–110.
- 412 27. European Parliament. EU AI Act: first regulation on artificial intelligence. Topics |
413 European Parliament.
414 2024[https://www.europarl.europa.eu/topics/en/article/20230601STO93804/eu-ai-act-first-](https://www.europarl.europa.eu/topics/en/article/20230601STO93804/eu-ai-act-first-regulation-on-artificial-intelligence)
415 [regulation-on-artificial-intelligence](https://www.europarl.europa.eu/topics/en/article/20230601STO93804/eu-ai-act-first-regulation-on-artificial-intelligence). Accessed 25 July 2024.
- 416 28. Ong Ly C, Unnikrishnan B, Tadic T, Patel T, Duhamel J, Kandel S *et al.* Shortcut
417 learning in medical AI hinders generalization: method for estimating AI model generalization
418 without external data. *NPJ Digit Med* 2024;**7**:124.
- 419 29. Xie C, Du R, Ho JW, Pang HH, Chiu KW, Lee EY *et al.* Effect of machine learning
420 re-sampling techniques for imbalanced datasets in 18F-FDG PET-based radiomics model on
421 prognostication performance in cohorts of head and neck cancer patients. *Eur J Nucl Med Mol*
422 *Imaging* 2020;**47**:2826–2835.
- 423 30. Bradshaw TJ, Huemann Z, Hu J, Rahmim A. A Guide to Cross-Validation for

- 424 Artificial Intelligence in Medical Imaging. *Radiol Artif Intell* 2023;**5**:e220232.
425 31. Willemink MJ, Koszek WA, Hardell C, Wu J, Fleischmann D, Harvey H *et al*.
426 Preparing Medical Imaging Data for Machine Learning. *Radiology* 2020;**295**:4–15.
427 32. Molwitz I, Ozga AK, Gerdes L, Ungerer A, Köhler D, Ristow I *et al*. Prediction of
428 abdominal CT body composition parameters by thoracic measurements as a new approach to
429 detect sarcopenia in a COVID-19 cohort. *Sci Rep* 2022;**12**:6443.
430